Calithera Biosciences (STU:2CB0) EBIT per Share : €-8.49 (TTM As of Dec. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences EBIT per Share?

Calithera Biosciences's EBIT per Share for the three months ended in Dec. 2022 was €-1.43. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 was €-8.49.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Calithera Biosciences's EBIT per Share or its related term are showing as below:

STU:2CB0's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Calithera Biosciences's EBIT for the three months ended in Dec. 2022 was €-6.94 Mil.

Calithera Biosciences EBIT per Share Historical Data

The historical data trend for Calithera Biosciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences EBIT per Share Chart

Calithera Biosciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-27.51

-35.34

-21.83

-15.47

-10.30

Calithera Biosciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EBIT per Share	Get a 7-Day Free Trial															-4.33	-3.20	-1.89	-1.98	-1.43

Calithera Biosciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Calithera Biosciences's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-39.718	/	3.8572
=	-10.30

Calithera Biosciences's EBIT per Share for the quarter that ended in Dec. 2022 is calculated as

	EBIT per Share		(Q: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.935	/	4.865
=	-1.43

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.49

Calithera Biosciences (STU:2CB0) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Calithera Biosciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Calithera Biosciences (STU:2CB0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (STU:2CB0) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080

Website

https://www.calithera.com

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Calithera Biosciences (STU:2CB0) Headlines

No Headlines